Experimental Pharmacology and New Targets in Cardiopulmonary Disorders

Our research group seeks to delve into the cellular and molecular bases of pulmonary vascular dysfunction, the gateway to the body for a multitude of agents capable of compromising people's health. Our research places a special focus on understanding endothelial damage and its connection with vascular smooth muscle and the immune system, all of which are very present in the development of rare or infrequent diseases such as pulmonary arterial hypertension and other cardiopulmonary disorders resulting from exposure to various environmental factors, such as hypoxia, certain pollutants, drugs or respiratory infections. The ultimate goal of our research will be to find new targets, biomarkers and therapeutic strategies that contribute, from basic biology and experimental pharmacology, to solving the health challenges of our society.